How teclistamab’s BCMA×CD3 mechanism works — and why it matters for heavily pre-treated patients

Teclistamab is a fully human bispecific antibody that simultaneously engages B-cell maturation antigen (BCMA) on malignant plasma cells and CD3 on T cells, physically bridging the two cell types to redirect cytotoxic T-cell killing against myeloma. This dual-target mechanism distinguishes it from conventional monoclonal antibodies and from CAR-T therapies, offering an off-the-shelf subcutaneous option for patients who have exhausted earlier lines of treatment.

The bispecific format solves a fundamental problem in myeloma immunotherapy: how to harness endogenous T cells without requiring costly and time-intensive manufacturing of personalised cell therapies. According to Janssen Biotech’s patent filings (WO2019154890A1 and its US family members), the anti-BCMA arm of teclistamab carries defined complementarity-determining regions (CDRs) that confer high-affinity, selective binding to BCMA, while the anti-CD3 arm activates T cells only when the bispecific is physically tethered to a BCMA-expressing target cell — a design intended to minimise off-tumour T-cell activation.

Subcutaneous delivery is a deliberate strategic choice. Janssen’s dosing-regimen patents (US20240101706A1) describe a step-up dosing protocol for initial treatment followed by weekly maintenance dosing at 1.5 mg/kg. The step-up design is intended to prime the immune system gradually, reducing the severity of cytokine release syndrome — one of the most clinically significant safety signals associated with T-cell-redirecting therapies. The same filings describe biomarker-guided dosing adjustments, signalling an intent to personalise the safety-efficacy balance at the individual patient level.

Janssen’s patent portfolio: mapping the teclistamab IP estate from molecule to method

Janssen Biotech’s teclistamab IP estate spans at least three distinct layers: composition-of-matter patents covering the antibody molecule itself, method-of-treatment patents covering specific patient populations, and dosing-regimen patents covering administration protocols. This layered approach is a deliberate strategy to extend commercial exclusivity beyond the core molecule patent and to create multiple enforcement positions against biosimilar entrants.

The foundational composition-of-matter application, WO2019154890A1, was filed in 2019 and has generated a large family of US continuation and divisional applications — including US11512132B2 (granted November 2022), US20230312727A1, US20240132613A1, and US20240218069A1, among others. Each continuation typically refines claim scope, adds new embodiments, or addresses examiner rejections, collectively building a thicket of overlapping protection around the core BCMA-binding CDR sequences that define teclistamab.

Method-of-treatment filings represent a second, strategically important layer. According to patent analysis via PatSnap’s innovation intelligence platform, filings such as US20230190794A1, US20220411517A1, and US20240010735A1 claim treatment methods for triple-class exposed (TCE) and triple-class refractory (TCR) patients — language that maps directly to the FDA’s approved indication language for Tecvayli. Additional method claims cover lenalidomide-refractory, pomalidomide-refractory, daratumumab-refractory, and prior anti-BCMA-treated populations, each representing a distinct claim set that could independently support enforcement or licensing.

Biomarker-based prediction of response represents a forward-looking element of the IP strategy. Filings including US20230272112A1, US20240010736A1, and related applications describe methods of predicting a patient’s response to teclistamab using biomarkers, alongside the treatment methods themselves. If validated clinically, such biomarker claims could support companion diagnostic development and create additional IP barriers for any competitor seeking to enter the BCMA-targeted bispecific space with a similar subcutaneous format.

Triple-class exposed and refractory patients: who teclistamab is designed to treat

The target population for teclistamab is defined with precision in Janssen’s patent filings: patients with multiple myeloma who are triple-class exposed (TCE) — meaning they have received at least one proteasome inhibitor, one immunomodulatory drug, and one anti-CD38 antibody — or who are triple-class refractory (TCR), meaning their disease has progressed on or within 60 days of completing each of those three drug classes.

This population represents one of the most difficult-to-treat groups in oncology. By the time patients become TCR, median survival without effective intervention is measured in months. The inclusion of daratumumab-refractory patients as a specific subpopulation in multiple patent filings (US20230190794A1, US20230190795A1, US20240010735A1) reflects the clinical reality that daratumumab — itself a transformative anti-CD38 antibody — has become standard of care in earlier lines, meaning most late-line myeloma patients will have prior anti-CD38 exposure by the time they are eligible for teclistamab.

“Janssen’s method-of-treatment patents explicitly cover patients who are lenalidomide-refractory, pomalidomide-refractory, daratumumab-refractory, and those with prior anti-BCMA treatment — a scope that maps almost precisely to the unmet need in later-line myeloma.”

The inclusion of prior anti-BCMA treatment as a covered population is particularly notable. It signals that Janssen is anticipating a treatment landscape in which patients may have received another BCMA-directed therapy — such as a BCMA-targeted CAR-T or belantamab mafodotin — before reaching teclistamab. Whether teclistamab retains meaningful activity after prior BCMA-directed therapy remains an active clinical question, but the patent coverage ensures that Janssen retains IP rights over any such use regardless of the clinical outcome data.

Combination strategies: daratumumab, gamma secretase inhibitors, and the rationale behind each

Janssen has filed two distinct combination-therapy patent families for teclistamab, each with a different mechanistic rationale. The first covers the doublet combination of teclistamab with daratumumab (US20240000938A1, US20240025994A1). The second — and more complex — covers a triple regimen of teclistamab, a gamma secretase inhibitor (GSI), and daratumumab (US20230295329A1).

The GSI combination rationale is scientifically significant because BCMA shedding — the proteolytic cleavage of surface BCMA into soluble BCMA (sBCMA) by gamma secretase — is a known resistance mechanism for BCMA-directed therapies. Elevated sBCMA in the tumour microenvironment can act as a decoy, sequestering teclistamab before it reaches cell-surface BCMA. By inhibiting gamma secretase, the GSI combination aims to reduce shedding, increase surface BCMA density, and restore sensitivity in patients who might otherwise be partially resistant. This mechanistic insight is documented in the patent filing itself, making it a matter of public record available to competitors and regulators alike.

The doublet combination with daratumumab alone (without a GSI) represents a potentially more clinically straightforward approach. Daratumumab is already widely used in earlier lines and has a well-characterised safety profile. Combining it with teclistamab in the relapsed/refractory setting could leverage daratumumab’s residual activity against CD38-expressing cells while teclistamab addresses BCMA-expressing myeloma clones — a complementary mechanism that the patent filing describes as potentially more effective than either agent individually. Research published by organisations including NEJM and ASCO has highlighted the growing interest in rational combination strategies in relapsed/refractory myeloma.

The GPRC5D race: how talquetamab creates a second front in Janssen’s myeloma franchise

Talquetamab targets GPRC5D — G protein-coupled receptor class C group 5 member D — a surface antigen expressed on myeloma cells that is entirely distinct from BCMA. Janssen Biotech holds patents covering both the anti-GPRC5D antibody molecule (US11673966B2, granted June 2023; US20240018267A1; US20230340132A1) and combination therapies using talquetamab alongside other agents (WO2021214100A2 and its US family members including US20230331836A1, US20230406956A1, and US20240000937A1).

The strategic significance of the GPRC5D target is rooted in its non-overlapping antigen expression relative to BCMA. Patients who have progressed on or become resistant to BCMA-directed therapies — whether teclistamab, belantamab mafodotin, or BCMA-targeted CAR-T — may retain GPRC5D expression on their myeloma cells, making talquetamab a viable subsequent or concurrent option. This creates a sequencing opportunity that Janssen is uniquely positioned to exploit, as it holds the key patents on both agents. As noted by the FDA, bispecific antibodies targeting novel myeloma antigens represent a clinically important class of therapeutics for patients with limited remaining options.

The talquetamab combination patent filings (WO2021214100A2, originally filed in 2021) predate the agent’s regulatory approval, reflecting Janssen’s practice of filing combination patents early in clinical development to establish priority dates before competitors can characterise similar combinations. The specific additional agents covered in the talquetamab combination filings are not fully enumerated in the public abstracts reviewed, but the filing architecture mirrors the teclistamab combination strategy — suggesting a systematic approach to building layered IP protection around each bispecific asset.

Patent strategy implications for drug developers and IP professionals

The teclistamab and talquetamab patent estates together illustrate a textbook example of layered pharmaceutical IP strategy — one that drug developers, IP professionals, and competitive intelligence teams should study carefully when entering or monitoring the relapsed/refractory myeloma space.

Several strategic patterns emerge from the patent landscape:

• Continuation filing strategy: The core BCMA antibody composition-of-matter application (WO2019154890A1, 2019) has been extended through a cascade of US continuation and divisional applications spanning 2021 to 2024, each potentially carrying a different patent term expiry date and claim scope. Competitors must navigate this thicket when designing around the teclistamab molecule.
• Method-of-treatment claims as a second line of defence: Even if composition-of-matter claims are successfully challenged or expire, the method-of-treatment patents covering specific TCE/TCR patient populations, dosing regimens, and biomarker-guided administration create independent enforcement positions that could block biosimilar or follow-on entrants from the most commercially valuable indications.
• Combination patents as a moat: By filing combination patents early — before clinical proof-of-concept data is published — Janssen establishes priority over the combination use cases that are most likely to become standard of care. Any competitor or academic institution that subsequently demonstrates the same combination will be operating within Janssen’s patent scope, potentially requiring a licence.
• Dual-asset sequencing: Holding patents on both BCMA-directed (teclistamab) and GPRC5D-directed (talquetamab) bispecifics gives Janssen the ability to patent sequential treatment regimens — teclistamab followed by talquetamab, or vice versa — as a proprietary treatment strategy, further extending the commercial life of both assets.

For drug developers considering entry into the BCMA or GPRC5D bispecific space, a thorough freedom-to-operate analysis against the full Janssen portfolio — including all continuation and divisional applications — is essential. The WIPO PatentScope database provides access to the PCT filings, while national office databases and platforms such as PatSnap enable comprehensive family-level analysis across jurisdictions.

For IP professionals advising innovators working on next-generation BCMA or GPRC5D therapeutics, the biomarker-based response-prediction claims in the teclistamab filings represent a particular area of concern: if a competitor develops a companion diagnostic for a similar bispecific, they may inadvertently infringe method claims that cover biomarker-guided patient selection for teclistamab. This is an area where claim construction analysis and potentially inter partes review (IPR) proceedings before the USPTO could become strategically important.